Samsung Biologics Co. Ltd.

05/13/2025 | Press release | Distributed by Public on 05/13/2025 20:44

Accelerating biomanufacturing facility readiness: A scalable validation model for multiproduct facilities

Resource Library

Whitepapers

Accelerating biomanufacturing facility readiness: A scalable validation model for multiproduct facilities


Facility readiness is essential for meeting project timelines - especially for multiproduct biologics manufacturing, as complexity and regulatory demands continue to evolve.


Samsung Biologics has developed a scalable validation framework leveraging its expertise acquired by building large-scale plants. Now applied to Plant 5, this strategy enables faster, compliant start-up across diverse client programs.


Facility readiness is essential for meeting project timelines - especially for multiproduct biologics manufacturing, as complexity and regulatory demands continue to evolve.


Samsung Biologics has developed a scalable validation framework leveraging its expertise acquired by building large-scale plants. Now applied to Plant 5, this strategy enables faster, compliant start-up across diverse client programs.

Attached
  • Accelerating biomanufacturing facility readiness: A scalable validation model for multiproduct facilities
Samsung Biologics Co. Ltd. published this content on May 13, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 14, 2025 at 02:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io